However, the causal association of CRP with atherogenesis is less clear, and there are data suggesting that it is a bystander rather than a true risk factor.
CRP levels decrease in response to anti-inflammatory agents, making it useful for monitoring the efficacy of novel anti-inflammatory drugs [18].